FCMT
NKTR icon

Founders Capital Management (Texas)’s Nektar Therapeutics NKTR Stock Holding History

Founders Capital Management (Texas)’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$8.46K – 416
2025
Q4 		$8.46K Buy
+200
New +$11.2K ﹤0.01% 325
2024
Q4 		– Sell
-47
Closed -$910 – 383
2024
Q3 		$910 Hold
47
– – ﹤0.01% 348
2024
Q2 		$868 Hold
47
– – ﹤0.01% 348
2024
Q1 		$654 Hold
47
– – ﹤0.01% 341
2023
Q4 		$396 Sell
47
-53
-53% -$401 ﹤0.01% 370
2023
Q3 		$893 Hold
100
– – ﹤0.01% 382
2023
Q2 		$863 Hold
100
– – ﹤0.01% 371
2023
Q1 		$1K Hold
100
– – ﹤0.01% 377
2022
Q4 		$3K Sell
100
-33
-25% -$1.6K ﹤0.01% 351
2022
Q3 		$6K Hold
133
– – ﹤0.01% 332
2022
Q2 		$8K Buy
133
+66
+99% +$4.16K 0.01% 341
2022
Q1 		$14K Hold
67
– – 0.01% 245
2021
Q4 		$14K Buy
+67
New +$14.5K 0.01% 245

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Founders Capital Management (Texas)'s NKTR Position: Q1 2026 in Review

Founders Capital Management (Texas) sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 200 shares — an estimated $8.46K sold.

Founders Capital Management (Texas) first reported a position in NKTR in Q4 2021 and held it in 13 quarters. The position peaked at $14K in Q1 2022. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Founders Capital Management (Texas) reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Founders Capital Management (Texas) sold 200 Nektar Therapeutics shares in Q1 2026, an estimated $8.46K.
  • Founders Capital Management (Texas) first reported a position in Nektar Therapeutics in Q4 2021 and held it in 13 quarters.
  • Founders Capital Management (Texas)'s Nektar Therapeutics position peaked at $14K in Q1 2022.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Founders Capital Management (Texas)'s 13F filing for Q1 2026, filed 21 Apr 2026.